Physician profile
Andrew Dawson
NPI 1093775934
$41,475.63
in general payments reported to CMS, 2019-2025
32 companies · $8,481 in 2025
The $8,481 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,734 · 2020: $233 · 2021: $888 · 2022: $6,069 · 2023: $907 · 2024: $21K · 2025: $8,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $3,006 · Travel and Lodging: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,431.25 |
| Food and Beverage | $3,005.64 |
| Travel and Lodging | $115.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,363.03 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Livanova USA, INC. | $4,030.48 | 2019-2022 | |
| Sk Life Science, INC. | $2,050.33 | 2021-2025 | Xcopri |
| Ucb, INC. | $915.75 | 2019-2025 | Rystiggo, Nayzilam |
| Neuropace, INC. | $449.71 | 2022-2024 | |
| Greenwich Biosciences, INC. | $439.63 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $328.46 | 2019-2020 | |
| Eisai INC. | $244.61 | 2019-2022 | |
| Allergan, INC. | $237.00 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $205.87 | 2025 | |
| Medtronic USA, INC. | $178.27 | 2019 | |
| Neurelis, INC. | $173.51 | 2024-2025 | Valtoco |
| Immedica Pharma US, INC. | $160.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $114.49 | 2019 | |
| Merz North America, INC. | $59.57 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $56.59 | 2020 | |
| Biogen, INC. | $51.70 | 2019 | |
| Csl Behring | $50.60 | 2019 | |
| Grifols USA, LLC | $50.11 | 2019 | |
| Avanos Medical | $43.62 | 2020 | |
| Emd Serono, INC. | $41.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $35.56 | 2023 | Rexulti |
| Zogenix INC. | $30.28 | 2020 | |
| Lundbeck LLC | $24.91 | 2019 | |
| Genzyme Corporation | $22.36 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.85 | 2022 | |
| Mallinckrodt Enterprises LLC | $19.51 | 2019 | |
| Acadia Pharmaceuticals INC | $19.21 | 2020 | |
| Merz Pharmaceuticals, LLC | $17.92 | 2022 | |
| Ge Healthcare | $14.04 | 2019 | |
| Lilly USA, LLC | $14.01 | 2019 | |
| Strongbridge US INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.